Get the Stockscreener App
1.74
3.87%
-0.07
After Hours:
1.74
Lava Therapeutics Nv stock is traded at $1.74, with a volume of 285.52K.
It is down -3.87% in the last 24 hours and up +16.78% over the past month.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.
See More
Previous Close:
$1.81
Open:
$1.81
24h Volume:
285.52K
Relative Volume:
0.84
Market Cap:
$45.77M
Revenue:
$4.99M
Net Income/Loss:
$-28.29M
P/E Ratio:
-1.6527
EPS:
-1.0528
Net Cash Flow:
$-36.20M
1W Performance:
+2.35%
1M Performance:
+16.78%
6M Performance:
+31.82%
1Y Performance:
+14.47%
1-Day Range:
$1.62
$1.82
1-Week Range:
$1.60
$1.825
52-Week Range:
$0.8502
$2.00
Lava Therapeutics Nv Stock (LVTX) Company Profile
Name
Lava Therapeutics Nv
Sector
Industry
Phone
31 6 3000 3035
Address
YALELAAN 62, UTRECHT
Compare LVTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LVTX
Lava Therapeutics Nv
|
1.74 | 47.61M | 4.99M | -28.29M | -36.20M | -1.0528 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.32 | 106.82B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.00 | 73.86B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
445.79 | 60.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.50 | 56.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
199.64 | 43.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lava Therapeutics Nv Stock (LVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-11-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Oct-25-22 | Initiated | H.C. Wainwright | Buy |
| Apr-19-21 | Initiated | JP Morgan | Overweight |
| Apr-19-21 | Initiated | Jefferies | Buy |
| Apr-19-21 | Initiated | SVB Leerink | Outperform |
View All
Lava Therapeutics Nv Stock (LVTX) Latest News
How LAVA Therapeutics N.V. (4PKB) stock expands through international markets2025 Breakouts & Breakdowns & Weekly Chart Analysis and Trade Guides - newser.com
What makes LAVA Therapeutics N.V. (4PKB) stock appealing to growth investorsQuarterly Earnings Report & Reliable Volume Spike Trade Alerts - newser.com
How LAVA Therapeutics N.V. (4PKB) stock trades in high volatilityChart Signals & Proven Capital Preservation Tips - newser.com
How LAVA Therapeutics N.V. stock performs during Fed tightening cyclesQuarterly Earnings Report & AI Based Buy/Sell Signal Reports - newser.com
Will LAVA Therapeutics N.V. stock benefit from AI adoptionAnalyst Downgrade & Real-Time Buy Signal Alerts - newser.com
Will LAVA Therapeutics N.V. (4PKB) stock justify high valuationWeekly Profit Report & Expert Curated Trade Setup Alerts - newser.com
Why hedge funds are buying LAVA Therapeutics N.V. stockJuly 2025 Setups & Entry Point Confirmation Signals - newser.com
Advanced analytics toolkit walkthrough for LAVA Therapeutics N.V.Sell Signal & High Yield Stock Recommendations - newser.com
Will LAVA Therapeutics N.V. stock benefit from green energy trendsWall Street Watch & Expert Curated Trade Ideas - newser.com
Can LAVA Therapeutics N.V. (4PKB) stock expand revenue streamsWeekly Investment Report & Technical Confirmation Alerts - newser.com
How to track smart money flows in LAVA Therapeutics N.V.2025 Winners & Losers & Daily Profit Focused Screening - newser.com
Is LAVA Therapeutics N.V. showing signs of accumulationWall Street Watch & Reliable Intraday Trade Alerts - newser.com
How LAVA Therapeutics N.V. stock valuations compare to rivals2025 Trade Ideas & Technical Confirmation Trade Alerts - newser.com
Why LAVA Therapeutics N.V. (4PKB) stock stays on buy listsWeekly Trade Analysis & Safe Swing Trade Setups - newser.com
Will LAVA Therapeutics N.V. (4PKB) stock outperform small cap peersWeekly Investment Recap & Intraday High Probability Setup Alerts - newser.com
Published on: 2025-11-19 00:31:28 - newser.com
Analyzing LAVA Therapeutics N.V. with risk reward ratio chartsPortfolio Gains Summary & Expert Approved Momentum Ideas - newser.com
Custom strategy builders for tracking LAVA Therapeutics N.V.July 2025 Levels & Weekly High Conviction Ideas - newser.com
LuxembourgXOMA Royalty Acquires LAVA Therapeutics - Mondaq
Lava Therapeutics Nv Stock (LVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lava Therapeutics Nv Stock (LVTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cooperatieve Gilde Healthcare | 10% Owner |
Oct 16 '25 |
Sale |
1.49 |
690,239 |
1,028,456 |
4,128,912 |
| Cooperatieve Gilde Healthcare | 10% Owner |
Oct 14 '25 |
Sale |
1.51 |
227,341 |
343,285 |
5,019,151 |
| Cooperatieve Gilde Healthcare | 10% Owner |
Oct 13 '25 |
Sale |
1.54 |
47,686 |
73,436 |
5,246,492 |
| Cooperatieve Gilde Healthcare | 10% Owner |
Oct 10 '25 |
Sale |
1.55 |
49,869 |
77,297 |
5,294,178 |
| Cooperatieve Gilde Healthcare | 10% Owner |
Oct 09 '25 |
Sale |
1.56 |
48,169 |
75,144 |
5,344,047 |
| Cooperatieve Gilde Healthcare | 10% Owner |
Oct 08 '25 |
Sale |
1.57 |
28,954 |
45,458 |
5,392,216 |
| Versant Venture Capital VI, L. | 10% Owner |
Sep 19 '25 |
Sale |
1.40 |
2,370,533 |
3,322,065 |
0 |
| Versant Venture Capital VI, L. | 10% Owner |
Sep 19 '25 |
Sale |
1.40 |
532,870 |
746,764 |
0 |
| Versant Venture Capital VI, L. | 10% Owner |
Sep 17 '25 |
Sale |
1.49 |
362,806 |
540,291 |
2,736,644 |
| Versant Venture Capital VI, L. | 10% Owner |
Sep 18 '25 |
Sale |
1.44 |
366,111 |
527,859 |
2,370,533 |
0.67%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):